These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 28362716)

  • 1. PharmGKB summary: sorafenib pathways.
    Gong L; Giacomini MM; Giacomini C; Maitland ML; Altman RB; Klein TE
    Pharmacogenet Genomics; 2017 Jun; 27(6):240-246. PubMed ID: 28362716
    [No Abstract]   [Full Text] [Related]  

  • 2. Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study.
    Boudou-Rouquette P; Narjoz C; Golmard JL; Thomas-Schoemann A; Mir O; Taieb F; Durand JP; Coriat R; Dauphin A; Vidal M; Tod M; Loriot MA; Goldwasser F; Blanchet B
    PLoS One; 2012; 7(8):e42875. PubMed ID: 22912756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.
    Huillard O; Boissier E; Blanchet B; Thomas-Schoemann A; Cessot A; Boudou-Rouquette P; Durand JP; Coriat R; Giroux J; Alexandre J; Vidal M; Goldwasser F
    Expert Opin Drug Saf; 2014 May; 13(5):663-73. PubMed ID: 24693873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib: targeting multiple tyrosine kinases in cancer.
    Hasskarl J
    Recent Results Cancer Res; 2014; 201():145-64. PubMed ID: 24756790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?
    Faivre S; de Gramont A; Raymond E
    Target Oncol; 2016 Aug; 11(4):565-7. PubMed ID: 26996978
    [No Abstract]   [Full Text] [Related]  

  • 6. Sorafenib (Nexavar) for thyroid cancer.
    Med Lett Drugs Ther; 2014 May; 56(1443):43-4. PubMed ID: 24869715
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of sorafenib in hepatocellular carcinoma.
    Gholam P
    Clin Adv Hematol Oncol; 2015 Apr; 13(4):232-4. PubMed ID: 26352581
    [No Abstract]   [Full Text] [Related]  

  • 8. In-vivo relation between plasma concentration of sorafenib and its safety in Chinese patients with metastatic renal cell carcinoma: a single-center clinical study.
    Mai H; Huang J; Zhang Y; Qu N; Qu H; Mei GH; Liu J; Xu X; Chen L
    Oncotarget; 2017 Jun; 8(26):43458-43469. PubMed ID: 28404979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group.
    Kim A; Widemann BC; Krailo M; Jayaprakash N; Fox E; Weigel B; Blaney SM
    Pediatr Blood Cancer; 2015 Sep; 62(9):1562-6. PubMed ID: 26207356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Geschwind JF; Chapiro J
    Clin Adv Hematol Oncol; 2016 Aug; 14(8):585-7. PubMed ID: 27487101
    [No Abstract]   [Full Text] [Related]  

  • 11. Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond.
    Gadaleta-Caldarola G; Divella R; Mazzocca A; Infusino S; Ferraro E; Filippelli G; Daniele A; Sabbà C; Abbate I; Brandi M
    Future Oncol; 2015; 11(16):2263-6. PubMed ID: 26260805
    [No Abstract]   [Full Text] [Related]  

  • 12. Response of Malignant Thymoma to Sorafenib.
    Bolzacchini E; Chini C; Pinotti G
    J Thorac Oncol; 2016 Oct; 11(10):e125-6. PubMed ID: 27663400
    [No Abstract]   [Full Text] [Related]  

  • 13. PharmGKB summary: pazopanib pathway, pharmacokinetics.
    Thorn CF; Sharma MR; Altman RB; Klein TE
    Pharmacogenet Genomics; 2017 Aug; 27(8):307-312. PubMed ID: 28678138
    [No Abstract]   [Full Text] [Related]  

  • 14. Sustained complete remission of advanced hepatocellular carcinoma with sorafenib therapy.
    Azmi AN; Chan WK; Goh KL
    J Dig Dis; 2015 Sep; 16(9):537-40. PubMed ID: 26147446
    [No Abstract]   [Full Text] [Related]  

  • 15. The use of lipid-coated nanodiamond to improve bioavailability and efficacy of sorafenib in resisting metastasis of gastric cancer.
    Zhang Z; Niu B; Chen J; He X; Bao X; Zhu J; Yu H; Li Y
    Biomaterials; 2014 May; 35(15):4565-72. PubMed ID: 24602567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A rare primary liver tumor that responded to sorafenib.
    Seino S; Tsuchiya A; Watanabe M
    Gastroenterology; 2014 Dec; 147(6):1226-7. PubMed ID: 25450081
    [No Abstract]   [Full Text] [Related]  

  • 17. Use of sorafenib in a corticotropin-secreting pancreatic neuroendocrine carcinoma.
    Graham U; Eatock M; Atkinson B
    Pancreas; 2014 Jul; 43(5):809-10. PubMed ID: 24921203
    [No Abstract]   [Full Text] [Related]  

  • 18. Complete Response to Full-Dose Sorafenib Treatment in an Elderly HCC Patient: a Case Report.
    de Stefano G; Iodice V; Farella N
    J Gastrointest Cancer; 2015 Dec; 46(4):430-3. PubMed ID: 25894635
    [No Abstract]   [Full Text] [Related]  

  • 19. Sorafenib-induced tumor response in a patient with metastatic epithelioid angiomyolipoma.
    Lee DW; Chang H; Kim YJ; Kim KM; Lee HJ; Lee JS
    J Clin Oncol; 2014 Apr; 32(11):e42-5. PubMed ID: 24449236
    [No Abstract]   [Full Text] [Related]  

  • 20. Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?
    Sacco R; Antonucci M; Bargellini I; Marceglia S; Mismas V; Cabibbo G
    Future Oncol; 2015; 11(17):2371-3. PubMed ID: 26270206
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.